Not Yet Recruiting OBSERVATIONAL NCT05988697

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

An Observational Phase II Study to Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib in Advanced Non-small Cell Lung Cancer Patients With BRAF V600E Mutation

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Conditions Advanced Cancer BRAF V600E Mutation NSCLC Stage IIIB NSCLC Stage IV NSCLC

Interventions Combind asprin with Trametinib and Dabrafenib

Updated 4 times since 2023 Last updated: Oct 11, 2023 Started: Nov 1, 2023 Primary completion: Sep 1, 2026 Completion: Apr 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Advanced Cancer and BRAF V600E Mutation, this trial is actively recruiting participants. The trial is conducted by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Nov 2023 — Jul 2024 [monthly]

Not Yet Recruiting
Sep 2023 — Nov 2023 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Data source: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.